Detailed company information
Quanterix Corporation, based in Billerica, Massachusetts, is a life sciences enterprise dedicated to pioneering and commercializing advanced digital immunoassay platforms. These sophisticated systems are designed to enhance precision health in both scientific research and diagnostic applications, reaching markets across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company's core offerings include several innovative instruments: The HD-X instrument, which provides highly sensitive and automated multiplex protein detection. The SR-X instrument, enabling researchers to leverage Simoa detection technology for diverse uses, such as the direct detection of nucleic acids. The SP-X instrument, which utilizes Simoa planar array technology for conducting multiplex chemiluminescent immunoassays. Alongside these platforms, Quanterix also supplies crucial consumables, including assay kits and reagents. In addition to its product line, the company delivers various contract research services, encompassing sample analysis, the development of custom "homebrew" assays, and other specialized research and development projects. Quanterix's operational focus spans critical health areas like neurology, oncology, cardiology, infectious diseases, and inflammation. Its clientele within the life science research sector primarily consists of laboratories affiliated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research organizations. Sales are managed through a multifaceted approach, combining a direct sales force, dedicated support organizations, and a network of distributors or sales agents. The company was initially incorporated in 2007 as Digital Genomics, Inc., before rebranding to Quanterix Corporation in August of the same year.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q2Released: Aug 10, 2026
Earnings Transcript for 2026 - Q1Released: May 06, 2026
Earnings Transcript for 2025 - Q4Released: Mar 03, 2026
Earnings Transcript for 2025 - Q3Released: Nov 10, 2025
Earnings Transcript for 2025 - Q2Released: Aug 09, 2025
Earnings Transcript for 2025 - Q1Released: May 12, 2025
Earnings Transcript for 2024 - Q4Released: Mar 17, 2025
Earnings Transcript for 2024 - Q3Released: Nov 12, 2024
Earnings Transcript for 2024 - Q1Released: May 08, 2024
Earnings Transcript for 2023 - Q4Released: Feb 29, 2024
Earnings Transcript for 2023 - Q3Released: Nov 07, 2023
Earnings Transcript for 2023 - Q2Released: Aug 08, 2023
Earnings Transcript for 2023 - Q1Released: May 13, 2023
Earnings Transcript for 2022 - Q4Released: Mar 06, 2023
Earnings Transcript for 2022 - Q3Released: Nov 08, 2022
Earnings Transcript for 2022 - Q2Released: Aug 08, 2022
Earnings Transcript for 2022 - Q1Released: May 10, 2022
Earnings Transcript for 2021 - Q4Released: Mar 01, 2022
Earnings Transcript for 2021 - Q3Released: Nov 06, 2021
Earnings Transcript for 2021 - Q2Released: Aug 08, 2021
Earnings Transcript for 2021 - Q1Released: May 09, 2021
Earnings Transcript for 2020 - Q4Released: Mar 02, 2021
Earnings Transcript for 2020 - Q3Released: Nov 08, 2020
Earnings Transcript for 2020 - Q2Released: Aug 09, 2020
LUNG Pulmonx Corporation
Quanterix Corporation's Q4 2025 earnings detail the planned incremental sales and marketing spend and phased headcount additions in 2026 to support LucentAD commercialization, aligned with regulatory and reimbursement milestones.
Read post
Dafinchi
